Latest Methylphenidate Stories

Researchers, funded by the U.S. Food and Drug Administration and the Agency for Health Research Quality, recently studied the cardiovascular risk of ADHD medications in adults. The study found little evidence that the medications increased the risk of heart events, such as heart attack, sudden cardiac death, and stroke. The concerns stem from the fact that some of the medications are able to slightly increase heart rate and blood pressure levels. According to the study,...

OAKLAND, Calif., Dec. 12, 2011 /PRNewswire/ -- Researchers have found little evidence of increased risk of heart attack, sudden cardiac death or stroke associated with use of medications used primarily to treat attention deficit hyperactivity disorder. Their population-based study included more than 150,000 adults aged 25-64 years who used ADHD medications. This new study, funded by the U.S. Food and Drug Administration and the Agency for Health Research Quality, is the largest...

When researchers asked why we are not more intelligent, given the adaptive evolutionary process, their conclusion was that problems would arise if we had too much intelligence. Thomas Hills of the University of Warwick and Ralph Hertwig of the University of Basel looked at a wide range of studies including drug studies of Ritalin patients, studies of people with autism, debilitating synaesthesia and neural disorders linked with enhanced brain growth. People with attention disorders take...

We put a lot of energy into improving our memory, intelligence, and attention. There are even drugs that make us sharper, such as Ritalin and caffeine. But maybe smarter isn’t really all that better. A new paper published in Current Directions in Psychological Science, a journal of the Association for Psychological Science, warns that there are limits on how smart humans can get, and any increases in thinking ability are likely to come with problems. The authors looked to evolution to...

GREENWOOD VILLAGE, Colo., Nov. 16, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it has received PTO notification of the allowance of two important U.S. patents. The first patent is directed to a unique class of compounds that combine elements of diketopiperazines (same class as Ampion(TM)) and methylphenidate...

ORLANDO, Fla., Nov. 2, 2011 /PRNewswire-USNewswire/ -- Physicians should look for signs of substance abuse in teenagers who suffer from attention deficit hyperactivity disorder (ADHD), according to Philip L. Creps, DO, who shared his concerns over the correlation between the two behavioral disorders with his fellow osteopathic physicians (DOs) during the American Osteopathic Association's (AOA) OMED 2011, the Osteopathic Medical Conference & Exposition at the Orange County Convention...

ROCKVILLE, Md., Oct. 24, 2011 /PRNewswire-USNewswire/ -- Formal training in parenting strategies is a low-risk, effective method for improving behavior in preschool-age children at risk for developing attention deficit hyperactivity disorder (ADHD), while there is less evidence supporting the use of medications for children younger than 6 years old, according to a new report from the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ). The report...

Children with certain dopamine system gene variants have an improved response to methylphenidate - the most commonly prescribed medication for Attention Deficit Hyperactivity Disorder - in a finding that could help eliminate the guesswork from prescribing effective medications for children with ADHD. Researchers reporting their results in the Oct. 21 Journal of the American Academy of Child and Adolescent Psychiatry tested 89 children with ADHD between ages 7 and 11. They found that...

BASINGSTOKE, England, October 21, 2011 /PRNewswire/ -- Success of pivotal, phase III trial marks long-acting, prodrug stimulant LDX as potential new treatment option for ADHD in Europe For international medical media only Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged...

New guidelines from the American Academy of Pediatrics (AAP) offer new information on helping doctors diagnose and treat children with Attention-Deficit/Hyperactivity Disorder (ADHD). The guidelines describe the special considerations involved in diagnosing and treating children and adolescents. The new guidelines for children from ages 4 to 18 also help children with hyperactive/impulsive behaviors that do not meet the full diagnostic criteria for ADHD. "Treating children at a young...